Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 773.

https://doi.org/10.1182/blood.V120.21.773.773

Published: 2012

Journal Articles

Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia

Vera Magistroni, PhD, Nitesh Sharma, Rocco Piazza, MD, PhD, Jason G Harb, Ph.D, Roberta Spinelli, M.Sc., Alessandra Pirola, M.Sc., Justin Ellis, Kim Dong-Wook, Danilo Perrotti, MD, Ph.D, Carlo Gambacorti-Passerini, MD

Blood (2012) 120 (21): 3727.

https://doi.org/10.1182/blood.V120.21.3727.3727

Published: 2012

Journal Articles

Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients

Jason G Harb, Ph.D, Paolo Neviani, PhD, Claudia S Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2738.

https://doi.org/10.1182/blood.V118.21.2738.2738

Published: 2011

Journal Articles

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Xiaomeng Huang, Sebastian Schwind, MD, Bo Yu, Ph.D, Jiuxia Pang, Ramasamy Santhanam, Ph.D, Kenneth K. Chan, Ph.D, Ramiro Garzon, MD, William Blum, MD, Clara D. Bloomfield, MD, Shujun Liu, Ph.D, Danilo Perrotti, MD, Ph.D, Robert J. Lee, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, L. James Lee, Ph.D, Guido Marcucci, MD

Blood (2011) 118 (21): 81.

https://doi.org/10.1182/blood.V118.21.81.81

Published: 2011

Journal Articles

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

Alison R. Walker, MD, Klaus H. Metzeler, MD, Susan Geyer, PhD, Heiko Becker, MD, Sebastian Schwind, MD, Susan P. Whitman, PhD, John Curfman, Yue-Zhong Wu, MS, Danilo Perrotti, MD, Ph.D, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, William Blum, MD, Guido Marcucci, MD

Blood (2011) 118 (21): 944.

https://doi.org/10.1182/blood.V118.21.944.944

Published: 2011

Journal Articles

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, PhD, S. A Saddoughi, Paolo Neviani, PhD, Jason G Harb, Ph.D, Besim Ogretmen, PhD, Robert Bittman, Ph.D, Ross L Levine, MD, Alfonso Quintás-Cardama, MD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2494.

https://doi.org/10.1182/blood.V118.21.2494.2494

Published: 2011

Journal Articles

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, PhD, Jason G Harb, Ph.D, Carolyn Paisie, B.S., Guido Marcucci, MD, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 3758.

https://doi.org/10.1182/blood.V118.21.3758.3758

Published: 2011

Journal Articles

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

Joshua J. Oaks, BS, Ramasamy Santhanam, Ph.D., Roger Briesewitz, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 3548.

https://doi.org/10.1182/blood.V110.11.3548.3548

Published: 2007

Journal Articles

MicroRNAs Act as Decoy Molecules To Restore Granulocytic Maturation of Differentiation-Arrested BCR/ABL + Myeloid Precursors.

Anna M. Eiring, BS, Paolo Neviani, D.Sci., George A. Calin, MD, Ph.D., Denis C. Roy, MD, Carlo M. Croce, MD, Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 31.

https://doi.org/10.1182/blood.V110.11.31.31

Published: 2007

Journal Articles

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

Anna M. Eiring, BS, Paolo Neviani, D.Sci., Ramasamy Santhanam, Ph.D., Joshua J. Oaks, B.S., Ji Suk Chang, Ph.D., Carlo Gambacorti-Passerini, MD, Stefano Volinia, MD, Guido Marcucci, MD, Michael A. Caligiuri, MD, Gustavo W. Leone, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 33.

https://doi.org/10.1182/blood.V110.11.33.33

Published: 2007

Journal Articles

BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases.

Ji-Suk Chang, PhD, Mario Notari, MS, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2005) 106 (11): 4376.

https://doi.org/10.1182/blood.V106.11.4376.4376

Published: 2005

NARROW

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia

Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1 + in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34 + /CD38 − Stem and CD34 + progenitor Cells From CML-BC Patients

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

MicroRNAs Act as Decoy Molecules To Restore Granulocytic Maturation of Differentiation-Arrested BCR/ABL + Myeloid Precursors.

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only